Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial

Journal of General Virology

Volumn 87, Issue 2, 2006, Pages 399-410

  Burgers, Wendy A ^a   van Harmelen, Joanne H ^a   Shephard, Enid ^a,b   Adams, Craig ^a   Mgwebi, Thandiswa ^a   Bourn, William ^a   Hanke, Tomáš ^d   Williamson, Anna Lise ^a,c   Williamson, Carolyn ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; PLASMID VECTOR; PROTEIN ANTIBODY; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CODON; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYTOPLASM; DEVELOPING COUNTRY; DNA MODIFICATION; DNA SHUFFLING; DRUG DESIGN; DRUG MANUFACTURE; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; ENZYME ACTIVE SITE; EPIDEMIC; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC SELECTION; GENETIC VARIABILITY; GUINEA PIG; HEALTH PROGRAM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; MULTIGENE FAMILY; MYRISTYLATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; SEROTYPE; SOUTH AFRICA; UNITED STATES;

AIDS VACCINES; ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENES, ENV; GENES, GAG; GENES, TAT; HIV-1; HUMANS; MICE; VACCINES, DNA;

ANIMALIA; CAVIA; CAVIA PORCELLUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 31644435352     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81379-0     Document Type: Article

References (67)

1. Addo, M. M., Yu, X. G., Rathod, A. & 17 other authors (2003). Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77, 2081-2092.
2. Aiken, C., Konner, J., Landau, N. R., Lenburg, M. E. & Trono, D. (1994). Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76, 853-864.
3. Allen, T. M., O'Connor, D. H., Jing, P. & 16 other authors (2000). Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390.
4. Altfeld, M., Addo, M. M., Shankarappa, R. & 13 other authors (2003). Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 77, 7330-7340.
5. Amara, R. R., Villinger, F., Altman, J. D. & 19 other authors (2001). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74.
6. Amara, R. R., Smith, J. M., Staprans, S. I. & 13 other authors (2002). Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime /recombinant modified vaccinia virus Ankara vaccine. J Virol 76, 6138-6146.
7. Barouch, D. H. & Letvin, N. L. (2004). HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? Lancet 364, 10-11.
8. Barouch, D. H., Santra, S., Schmitz, J. E. & 26 other authors (2000). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492.
9. Barouch, D. H., Kunstman, J., Kuroda, M. J. & 11 other authors (2002). Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339.
10. Barouch, D. H., Yang, Z.-Y., Kong, W.-P. & 9 other authors (2005). A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79, 8828-8834.
11. Betti, M., Voltan, R., Marchisio, M., Mantovani, I., Boarini, C., Nappi, F., Ensoli, B. & Caputo, A. (2001). Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. Vaccine 19, 3408-3419.
12. + T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75, 11983-11991.
13. Boykins, R. A., Mahieux, R., Shankavaram, U. T. & 8 other authors (1999). Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. J Immunol 163, 15-20.
14. Buseyne, F., Le Chenadec, J., Corre, B., Porrot, F., Burgard, M., Rouzioux, C., Blanche, S., Mayaux, M.-J. & Rivière, Y. (2002). Inverse correlation between memory Gag-specific cytotoxic T lymphocytes and viral replication in human immunodeficiency virus-infected children. J Infect Dis 186, 1589-1596.
15. Casimiro, D. R., Tang, A. M., Perry, H. C. & 15 other authors (2002). Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol 76, 185-194.
16. Chao, S.-F., Chan, V. L., Juranka, P., Kaplan, A. H., Swanstrom, R. & Hutchison, C. A., III (1995). Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 23, 803-810.
17. Connick, E., Schlichtemeier, R. L., Purner, M. B. & 8 other authors (2001). Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. J Infect Dis 184, 1465-1469.
18. Coplan, P. M., Gupta, S. B., Dubey, S. A. & 23 other authors (2005). Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 191, 1427-1434.
19. Cranenburgh, R. M., Hanak, J. A. J., Williams, S. G. & Sherratt, D. J. (2001). Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 29, e26.
20. Department of Health South Africa (2005). National HIV and Syphilis Antenatal Sero-prevalence Survey in South Africa 2004. http://www.doh.gov.za/docs/reports/2004/hiv-syphilis.pdf
21. Edwards, T. G., Wyss, S., Reeves, J. D., Zolla-Pazner, S., Hoxie, J. A., Doms, R. W. & Baribaud, F. (2002). Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 76, 2683-2691.
22. Ferrari, G., Humphrey, W., McElrath, M. J., Excler, J. L., Duliege, A. M., Clements, M. L., Corey, L. C., Bolognesi, D. P. & Weinhold, K. J. (1997). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94, 1396-1401.
23. Gao, F., Weaver, E. A., Lu, Z. J. & 13 other authors (2005). Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 79, 1154-1163.
24. Gaschen, B., Taylor, J., Yusim, K. & 8 other authors (2002). AIDS diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360.
25. Guevara, H., Johnston, E., Zijenah, L., Tobalwa, O., Mason, P., Contag, C., Mahomed, K., Hendry, M. & Katzenstein, D. (2000). Prenatal transmission of subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in maternal and cord blood. J Acquir Immune Defic Syndr 25, 390-397.
26. Hanke, T. & McMichael, A. J. (2000). Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6, 951-955.
27. Hanke, T., Schneider, J., Gilbert, S. C., Hill, A. V. S. & McMichael, A. (1998). DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16, 426-435.
28. Hanke, T., Neumann, V. C., Blanchard, T. J., Sweeney, P., Hill, A. V. S., Smith, G. L. & McMichael, A. (1999). Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17, 589-596.
29. Hasson, T., Gillespie, P. G., Garcia, J. A., MacDonald, R. B., Zhao, Y., Yee, A. G., Mooseker, M. S. & Corey, D. P. (1997). Unconventional myosins in inner-ear sensory epithelia. J Cell Biol 137, 1287-1307.
30. Hussein, M., Abebe, A., Pollakis, G., Brouwer, M., Petros, B., Fontanet, A. L. & Rinke de Wit, T. F. (2000). HIV-1 subtype C in commercial sex workers in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr 23, 120-127.
31. HVTN (2005). The Pipeline Project: Vaccines in Development. http://chi.ucsf.edu/vaccines/
32. IAVI (2005). IAVI Report: Ongoing Trials of Preventative HIV Vaccines. http://www.iavireport.org/specials/ OngoingTrialsofpreventiveHIVVaccines.asp
33. Kaufmann, D. E., Bailey, P. M., Sidney, J. & 12 other authors (2004). Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 78, 4463-4477.
34. Kjerrström, A., Hinkula, J., Engström, G., Ovod, V., Krohn, K., Benthin, R. & Wahren, B. (2001). Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 284, 46-61.
35. Kong, W.-P., Huang, Y., Yang, Z.-Y., Chakrabarti, B. K., Moodie, Z. & Nabel, G. J. (2003). Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77, 12764-12772.
36. Korber, B., Gaschen, B., Yusim, K., Thakallapally, R., Kesmir, C. & Detours, V. (2001). Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58, 19-42.
37. Letvin, N. L., Huang, Y., Chakrabarti, B. K. & 15 other authors (2004). Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 78, 7490-7497.
38. Lichterfeld, M., Yu, X. G., Cohen, D. & 11 other authors (2004). HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS 18, 1383-1392.
39. Lole, K S., Bollinger, R. C., Paranjape, R. S., Gadkari, D., Kulkarni, S. S., Novak, N. G., Ingersoll, R., Sheppard, H. W. & Ray, S. C. (1999). Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73, 152-160.
40. Lynch, J. A., deSouza, M., Robb, M. D., Markowitz, L., Nitayaphan, S., Sapan, C. V., Mann, D. L., Birx, D. L. & Cox, J. H. (1998). Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J Infect Dis 178, 1040-1046.
41. + T cells: correlation with viral load. J Virol 78, 3233-3243.
42. McConkey, S. J., Reece, W. H. H., Moorthy, V. S. & 25 other authors (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9, 729-735.
43. Moorthy, V. S., Pinder, M., Reece, W. H. H. & 8 other authors (2003). Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 188, 1239-1244.
44. Moorthy, V. S., Imoukhuede, E. B., Keating, S., Pinder, M., Webster, D., Skinner, M. A., Gilbert, S. C., Walraven, G. & Hill, A. V. S. (2004). Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 189, 2213-2219.
45. Muthumani, K., Kudchodkar, S., Zhang, D., Bagarazzi, M. L., Kim, J. J., Boyer, J. D., Ayyavoo, V., Pavlakis, G. N. & Weiner, D. B. (2002). Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine 20, 1999-2003.
46. Mwau, M., Cebere, I., Sutton, J. & 16 other authors (2004). A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85, 911-919.
47. Nkolola, J. P., Wee, E. G.-T., Im, E.-J., Jewell, C. P., Chen, N., Xu, X.-N., McMichael, A. J. & Hanke, T. (2004). Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 11, 1068-1080.
48. Novitsky, V., Rybak, N., McLane, M. F. & 13 other authors (2001). Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 75, 9210-9228.
49. Novitsky, V., Cao, H., Rybak, N. & 9 other authors (2002). Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76, 10155-10168.
50. Osmanov, S., Pattou, C., Walker, N., Schwardlander, B. & Esparza, J. (2002). Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 29, 184-190.
51. Park, J., Ryu, J., Kim, K.-A. & 7 other authors (2002). Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells. J Gen Virol 83, 1173-1181.
52. Ramalingam, S., Kannangai, R., Vijayakumar, T. S., Mathai, D., Abraham, O. C., Subramanian, S., Purpali, P., Jesudason, M. V. & Sridharan, G. (2005). Subtype and cytokine profiles of HIV infected individuals from south India. Indian J Med Res 121, 226-234.
53. Robinson, H. L., Montefiori, D. C., Johnson, R. P. & 14 other authors (1999). Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5, 526-534.
54. Sadagopal, S., Amara, R. R., Montefiori, D. C., Wyatt, L. S., Staprans, S. I., Kozyr, N. L., McClure, H. M., Moss, B. & Robinson, H. L. (2005). Signature for long-term vaccine-mediated control of a simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. J Virol 79, 3243-3253.
55. Schwartz, O., Maréchal, V., Le Gall, S., Lemonnier, F. & Heard, J.-M. (1996). Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2, 338-342.
56. Seaman, M. S., Xu, L., Beaudry, K. & 11 other authors (2005). Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79, 2956-2963.
57. Shiver, J. W., Fu, T.-M., Chen, L. & 49 other authors (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
58. Smith, J. M., Amara, R. R., McClure, H. M. & 13 other authors (2004). Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in macaques. AIDS Res Hum Retroviruses 20, 654-665.
59. Travers, S. A. A., Clewley, J. P., Glynn, J. R., Fine, P. E. M., Crampin, A. C., Sibande, F., Mulawa, D., McInerney, J. O. & McCormack, G. P. (2004). Timing and reconstruction of the most recent common ancestor of the subtype C clade of human immunodeficiency virus type 1. J Virol 78, 10501-10506.
60. UNAIDS (2004). Report on the Global HIV/AIDS Epidemic. 4th Global Report. http://www.unaids.org
61. van Harmelen, J. H., van der Ryst, E., Loubser, A. S., York, D., Madurai, S., Lyons, S., Wood, R. & Williamson, C. (1999). A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res Hum Retroviruses 15, 395-398.
62. van Harmelen, J. H., Shephard, E., Thomas, R., Hanke, T., Williamson, A.-L. & Williamson, C. (2003). Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine 21, 4380-4389.
63. Vuola, J. M., Keating, S., Webster, D. P., Berthoud, T., Dunachie, S., Gilbert, S. C. & Hill, A. V. S. (2005). Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174, 449-455.
64. Vzorov, A. N., Lea-Fox, D. & Compans, R. W. (1999). Immunogenicity of full length and truncated SIV envelope proteins. Viral Immunol 12, 205-215.
65. Wild, J., Bojak, A., Deml, L. & Wagner, R. (2004). Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model. Vaccine 22, 1732-1743.
66. Williams, S. G., Cranenburgh, R. M., Weiss, A. M. E., Wrighton, C. J., Sherratt, D. J. & Hanak, J. A. J. (1998). Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26, 2120-2124.
67. Williamson, C., Morris, L., Maughan, M. F. & 12 other authors (2003). Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 19, 133-144.